Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives Consensus Recommendation of “Hold” from Brokerages

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) has received an average rating of “Hold” from the five ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $5.00.

A number of research firms recently weighed in on CTXR. Citigroup reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday. Wall Street Zen downgraded Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Zacks Research upgraded Citius Pharmaceuticals to a “hold” rating in a report on Tuesday, May 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Wednesday, June 24th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday.

Citius Pharmaceuticals Stock Performance

Shares of CTXR opened at $0.57 on Wednesday. The stock has a market cap of $15.70 million, a PE ratio of -0.27 and a beta of 1.03. Citius Pharmaceuticals has a fifty-two week low of $0.47 and a fifty-two week high of $2.19. The firm’s 50-day simple moving average is $0.58 and its two-hundred day simple moving average is $0.69.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its earnings results on Friday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.02. The business had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $5.46 million. Equities research analysts predict that Citius Pharmaceuticals will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new position in shares of Citius Pharmaceuticals in the second quarter worth approximately $32,000. NewEdge Advisors LLC bought a new stake in shares of Citius Pharmaceuticals during the second quarter valued at approximately $40,000. Asset Advisory Group Inc. purchased a new position in Citius Pharmaceuticals in the 4th quarter worth approximately $46,000. Heights Capital Management Inc. bought a new position in Citius Pharmaceuticals in the 4th quarter valued at approximately $622,000. Finally, BlackRock Inc. bought a new position in Citius Pharmaceuticals in the 2nd quarter valued at approximately $42,000. 16.88% of the stock is owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical?stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital?acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter?related bloodstream infections without catheter removal.